Blood cancers

Ibrutinib shows promise in CNS lymphoma

Ibrutinib appears useful in the setting of primary and secondary CNS lymphoma but there is little data on the optimal way to use it in such a rare disease, Australian clinicians have found. It will be a case of continuing to accumulate the data as the drug is used in this indication, according to findings ...

Already a member?

Login to keep reading.

© 2021 the limbic